$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000145368718000052 Filed on August 08, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$0.00	$0.00	$26.00K
YoY Change	-100.0%	-100.0%	-98.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.060M	$4.360M	$4.900M
YoY Change	-7.31%	-11.02%	102.48%
% of Gross Profit
Research & Development	$11.89M	$14.41M	$10.99M
YoY Change	25.05%	31.04%	83.23%
% of Gross Profit
Depreciation & Amortization	$200.0K	$400.0K	$200.0K
YoY Change	0.0%	100.0%	0.0%
% of Gross Profit
Operating Expenses	$15.94M	$18.77M	$15.90M
YoY Change	14.84%	18.07%	88.85%
Operating Profit	-$15.94M	-$18.77M	-$15.87M
YoY Change	15.06%	18.26%	147.95%
Interest Expense	$384.0K	$365.0K	$279.0K
YoY Change	43.28%	30.82%	-10.0%
% of Operating Profit
Other Income/Expense, Net	$3.000K	$8.000K	$0.00
YoY Change	-118.75%		-100.0%
Pretax Income	-$16.00M	-$18.80M	-$15.97M
YoY Change	8.99%	17.72%	130.78%
Income Tax
% Of Pretax Income
Net Earnings	-$16.00M	-$18.80M	-$15.97M
YoY Change	9.03%	17.72%	130.64%
Net Earnings / Revenue			-61411.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$714.3K	-$840.8K	-$849.0K
COMMON SHARES
Basic Shares Outstanding	22.40M shares	22.35M shares	18.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.50M	$66.20M	$112.7M
YoY Change	-51.63%	-41.26%	33.37%
Cash & Equivalents	$50.49M	$60.24M	$82.63M
Short-Term Investments	$0.00	$6.000M	$30.00M
Other Short-Term Assets	$5.100M	$2.600M	$1.900M
YoY Change	70.0%	36.84%	-24.0%
Inventory
Prepaid Expenses
Receivables			$1.000K
Other Receivables			$0.00
Total Short-Term Assets	$55.57M	$68.84M	$114.6M
YoY Change	-48.24%	-39.92%	28.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.109M	$2.137M	$2.131M
YoY Change	2.63%	0.28%	6.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.600M	$2.500M	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$4.755M	$4.602M	$2.447M
YoY Change	100.55%	88.07%	6.39%
TOTAL ASSETS
Total Short-Term Assets	$55.57M	$68.84M	$114.6M
Total Long-Term Assets	$4.755M	$4.602M	$2.447M
Total Assets	$60.32M	$73.44M	$117.0M
YoY Change	-45.02%	-37.25%	28.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.252M	$1.789M	$4.280M
YoY Change	-17.58%	-58.2%	375.56%
Accrued Expenses	$10.22M	$10.18M	$8.595M
YoY Change	56.07%	18.49%	95.34%
Deferred Revenue	$1.863M	$1.918M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$21.30M		$4.600M
YoY Change			155.56%
Total Short-Term Liabilities	$34.63M	$13.89M	$20.05M
YoY Change	205.88%	-30.73%	125.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$21.20M	$5.700M
YoY Change	-100.0%	271.93%	-43.56%
Other Long-Term Liabilities	$1.800M	$1.104M	$1.250M
YoY Change	44.0%	-11.68%	-64.29%
Total Long-Term Liabilities	$1.800M	$1.104M	$1.250M
YoY Change	44.0%	-11.68%	-90.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.63M	$13.89M	$20.05M
Total Long-Term Liabilities	$1.800M	$1.104M	$1.250M
Total Liabilities	$50.32M	$49.18M	$38.84M
YoY Change	12.71%	26.6%	72.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$263.2M	-$247.2M	-$182.7M
YoY Change	33.37%	35.32%
Common Stock	$3.000K	$3.000K	$1.000K
YoY Change	50.0%	200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.402M	$21.66M	$78.18M
YoY Change
Total Liabilities & Shareholders Equity	$60.32M	$73.44M	$117.0M
YoY Change	-45.02%	-37.25%	28.18%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$16.00M	-$18.80M	-$15.97M
YoY Change	9.03%	17.72%	130.64%
Depreciation, Depletion And Amortization	$200.0K	$400.0K	$200.0K
YoY Change	0.0%	100.0%	0.0%
Cash From Operating Activities	-$16.03M	-$16.97M	-$8.610M
YoY Change	3.82%	97.1%	53.75%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$270.0K	-$400.0K
YoY Change	-50.0%	-32.5%	566.67%
Acquisitions
YoY Change
Other Investing Activities	$6.070M	$18.95M	$11.09M
YoY Change	-370.98%	70.87%	60.03%
Cash From Investing Activities	$6.020M	$18.68M	$10.70M
YoY Change	-352.94%	74.58%	55.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	260.0K	310.0K	53.94M
YoY Change	-96.46%	-99.43%	-15.97%
NET CHANGE
Cash From Operating Activities	-16.03M	-16.97M	-8.610M
Cash From Investing Activities	6.020M	18.68M	10.70M
Cash From Financing Activities	260.0K	310.0K	53.94M
Net Change In Cash	-9.750M	2.020M	56.03M
YoY Change	-6.97%	-96.39%	-14.41%
FREE CASH FLOW
Cash From Operating Activities	-$16.03M	-$16.97M	-$8.610M
Capital Expenditures	-$60.00K	-$270.0K	-$400.0K
Free Cash Flow	-$15.97M	-$16.70M	-$8.210M
YoY Change	4.24%	103.41%	48.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22396183	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2017Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	859000	USD
CY2018Q2	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	528000	USD
CY2017Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1020000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26000	USD
CY2018Q2	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1023000	USD
CY2017Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2018Q2	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2017Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	268000	USD
CY2018Q2	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	699000	USD
CY2017Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	72000	USD
CY2018Q2	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	94000	USD
CY2017Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	3578000	USD
CY2018Q2	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	5210000	USD
CY2017Q4	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	70698000	USD
CY2018Q2	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	60237000	USD
CY2018Q1	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	70698000	USD
CY2018Q2	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	14788000	USD
CY2018Q1	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	14876000	USD
	selb	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	0	USD
	selb	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	88000	USD
	selb	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	0	USD
CY2018Q2	selb	Contractwith Customer Liability Other ContractwithCustomerLiabilityOther	2126000	USD
CY2018Q1	selb	Contractwith Customer Liability Other ContractwithCustomerLiabilityOther	2231000	USD
CY2018Q2	selb	Contractwith Customer Liability Other Current ContractwithCustomerLiabilityOtherCurrent	1000000	USD
	selb	Contractwith Customer Liability Other Increase From Cash Receipts ContractwithCustomerLiabilityOtherIncreaseFromCashReceipts	0	USD
CY2018Q2	selb	Contractwith Customer Liability Other Noncurrent ContractwithCustomerLiabilityOtherNoncurrent	1100000	USD
	selb	Contractwith Customer Liability Other Revenue Recognized ContractwithCustomerLiabilityOtherRevenueRecognized	105000	USD
	selb	Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger	300000	USD
	selb	Debt Instrument Event Of Default Minimum Assets Trigger DebtInstrumentEventOfDefaultMinimumAssetsTrigger	300000	USD
CY2018Q2	selb	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	6000000	USD
CY2018Q2	selb	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	2	position
CY2017Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
CY2018Q2	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
	selb	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P4Y
CY2016Q4	selb	License And Option Agreement Number Of Additional Targets For Which Other Party May Exercise Options For Additional Licenses LicenseAndOptionAgreementNumberOfAdditionalTargetsForWhichOtherPartyMayExerciseOptionsForAdditionalLicenses	4	target
CY2018Q1	selb	Number Of Collaboration Agreements Under Analysis To Quantify Impact Of Adoption NumberOfCollaborationAgreementsUnderAnalysisToQuantifyImpactOfAdoption	3	agreement
CY2018Q2	selb	Reimbursement Invoice ReimbursementInvoice	100000	USD
CY2018Q2	selb	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.178
	selb	Tax Cutsand Jobs Act Changein Tax Rate Increase Decrease In Deferred Tax Asset TaxCutsandJobsActChangeinTaxRateIncreaseDecreaseInDeferredTaxAsset	-23400000	USD
	selb	Tax Cutsand Jobs Act Valuation Allowance Deferred Tax Asset Increase Decrease Amount TaxCutsandJobsActValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount	23400000	USD
CY2018Q2	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1789000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-160000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	91000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10184000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4158000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4407000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4476000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	275888000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	863000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1558000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1286000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2439000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2320166	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3459102	shares
CY2017Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	5100	sqft
CY2017Q4	us-gaap	Assets Assets	101100000	USD
CY2018Q2	us-gaap	Assets Assets	73437000	USD
CY2018Q1	us-gaap	Assets Assets	103698000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	98680000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	68835000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	98911000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25956000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5992000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25956000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	5992000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25940000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	5991000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25940000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5991000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	183000	USD
CY2018Q2	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	2600000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82630000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60237000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59050000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83020000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71027000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60566000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23970000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10461000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3868662	shares
CY2018Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4932929	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22343254	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22396183	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22343254	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22396183	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30996000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18874000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34740000	USD
CY2018Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16914000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17107000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	787000	USD
CY2018Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1918000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	787000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15919000	USD
CY2018Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	12870000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	14089000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	193000	USD
CY2017Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0701
CY2017Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	98000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2018Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	386000	USD
CY2018Q2	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	600000	USD
	us-gaap	Depreciation Depreciation	584000	USD
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.67
	us-gaap	Interest Expense InterestExpense	579000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	80000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-71000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1902000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1815000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	82000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-83000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	84000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	71000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	22000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4903000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8778000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4362000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9036000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2254000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	155000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-215000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5636000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1167000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-90000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-88000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1356000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	107000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	279000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	365000	USD
	us-gaap	Interest Expense InterestExpense	715000	USD
	us-gaap	Interest Paid InterestPaid	461000	USD
	us-gaap	Interest Paid InterestPaid	539000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	89000	USD
CY2018Q2	us-gaap	Interest Payable Current InterestPayableCurrent	94000	USD
CY2017Q2	us-gaap	Investment Income Net InvestmentIncomeNet	101000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	214000	USD
CY2018Q2	us-gaap	Investment Income Net InvestmentIncomeNet	246000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	534000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	49286000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	49175000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	47456000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101100000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73437000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103698000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13891000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2018Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15871000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	15897000	USD
	us-gaap	Operating Expenses OperatingExpenses	30816000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	18769000	USD
	us-gaap	Operating Expenses OperatingExpenses	34582000	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
CY2018Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	21212000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	25000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	15000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53654000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	362000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5834000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19630000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23930000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30382000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-15967000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31101000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-18796000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34684000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30653000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18769000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34582000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2581000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	375000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1482000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	724000	USD
CY2017Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
CY2018Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	617000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	546000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-43000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	80000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-90000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-71000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-56000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	25000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	12000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000	USD
CY2018Q2	us-gaap	Other Liabilities OtherLiabilities	2100000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1104000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10994000	USD
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2042000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2607000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22038000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14407000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25546000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	74000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	204000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	265000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	459000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	456000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	32522000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	13900000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2273000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	49986000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	27147000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	33955000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	31000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	504000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	311000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	51000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6249000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6544000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2137000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1836000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	316000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	329000	USD
CY2017Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	329000	USD
CY2018Q2	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2465000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216897000	USD
CY2018Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2696000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216900000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	163000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-247153000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-247200000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212469000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22396183	shares
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2018Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	8600000	USD
	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod	P12M
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18814570	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18645339	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22355603	shares
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	5991000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	51814000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	24262000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	56242000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22350591	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in Russian bank accounts, of which </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> was held in U.S. dollars.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any off-balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, accounting for stock-based compensation and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>

Files In Submission

Name	View Source	Status
0001453687-18-000052-index-headers.html	Edgar Link	pending
0001453687-18-000052-index.html	Edgar Link	pending
0001453687-18-000052.txt	Edgar Link	pending
0001453687-18-000052-xbrl.zip	Edgar Link	pending
exhibit102_omidxfconsulting.htm	Edgar Link	pending
exhibit103_non-eexdircompp.htm	Edgar Link	pending
exhibit311_6302018.htm	Edgar Link	pending
exhibit312_6302018.htm	Edgar Link	pending
exhibit321_6302018.htm	Edgar Link	pending
exhibit322_6302018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20180630.xml	Edgar Link	completed
selb-20180630.xsd	Edgar Link	pending
selb-20180630_cal.xml	Edgar Link	unprocessable
selb-20180630_def.xml	Edgar Link	unprocessable
selb-20180630_lab.xml	Edgar Link	unprocessable
selb-20180630_pre.xml	Edgar Link	unprocessable
selectabiosciences10-q6302.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2018 Q3 Form 10-Q Financial Statement

#000145368718000052 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2018 Q3 Form 10-Q Financial Statement

#000145368718000052 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac